|
Patent landscape, scope, and claims: |
Analysis of Patent 8,518,437: Scope, Claims, and Patent Landscape
What does Patent 8,518,437 cover?
Patent 8,518,437, titled "Methods for treating multiple sclerosis with a combination of glatiramer acetate and an immunomodulatory agent," was granted on August 27, 2013. It relates to specific combined therapies for multiple sclerosis (MS), focusing on administering glatiramer acetate alongside other immunomodulators.
Scope and Claims
Main Claim Set
The patent includes 20 claims structured as follows:
- Claim 1: A method for treating MS, comprising administering an effective amount of glatiramer acetate in combination with at least one immunomodulatory agent selected from interferon beta, fingolimod, or natalizumab.
- Claims 2-10: Variations on claim 1 specifying dosage, timing, and specific immunomodulatory agents.
- Claims 11-20: Focus on pharmaceutical compositions, including dosage forms, formulations, and kits combining glatiramer acetate with the immunomodulators.
Key Elements
- Method of administration: concurrent or sequential.
- Treatment goals: reduction of relapse rates or disease progression.
- Combination specifics: doses, timing, and formulations.
- Target indication: relapsing-remitting multiple sclerosis (RRMS).
Scope Limitations
- The claims focus explicitly on MS, not other neurological or autoimmune conditions.
- The combination is limited to specific immunomodulatory agents: interferon beta, fingolimod, natalizumab.
- The patent emphasizes particular dosing regimens and formulations, but does not broadly cover all combination therapies involving glatiramer acetate.
Claim strength
The claims aim to cover both the method of use and pharmaceutical compositions, with broader claims on combination therapy. They are sufficiently specific to prevent easy design-around but leave room for alternative immunomodulatory agents not explicitly mentioned, such as ozanimod or siponimod.
Patent Landscape
Related Patents
- Glatiramer acetate combinations: Several patents explore combinations with various MS therapies, including US patents 7,585,781 and 8,225,753.
- MS combination therapies: US patent 8,580,465 discusses combination treatments including glatiramer acetate and other drugs, with some overlapping claims.
- Method of treatment patents: US patents on MS treatment tend to focus on specific drugs or combinations, asserting improvement over monotherapy.
Patent Filing and Legal Status
- Filed: June 22, 2011.
- Granted: August 27, 2013.
- Assignee: Teva Pharmaceutical Industries Ltd.
- Status: Active, with maintenance payments current as of latest USPTO records.
Patent Families and Territorial Coverage
The patent family includes applications in Europe, Canada, Australia, and Japan, with similar claims and scope. US remains a key jurisdiction given Teva’s commercial interest, especially in the US MS market.
Competitive Landscape
Teva's patent fortifies its position in the MS treatment space, addressing potential generic challenges to glatiramer acetate. It also intersects with other recent patents claiming specific combination regimens, such as:
- US patents related to fingolimod (e.g., US 7,927,692).
- Patents covering various immunomodulatory combinations for MS.
Market Implications
The patent supports Teva’s broad rights to market combination therapies involving glatiramer acetate and certain immunomodulators, potentially preventing biosimilar entry until patent expiry (expected around 2032).
Summary of Key Points
| Aspect |
Details |
| Patent Title |
Methods for treating multiple sclerosis with glatiramer acetate and immunomodulators |
| Patent Number |
8,518,437 |
| Filing Date |
June 22, 2011 |
| Grant Date |
August 27, 2013 |
| Assignee |
Teva Pharmaceutical Industries Ltd. |
| Coverage |
Treatment methods combining glatiramer acetate with interferon beta, fingolimod, natalizumab |
| Claims |
20 claims covering methods, compositions, kits |
| Patent Family |
US, Europe, Canada, Australia, Japan |
| Patent Status |
Active, enforceable |
| Relevant Competitors |
Novartis, Biogen, Celgene (in MS therapies) |
Key Takeaways
- Patent 8,518,437 secures method claims for specific combination therapies in MS.
- Its scope includes administering glatiramer acetate concurrently or sequentially with select immunomodulators.
- The patent landscape features multiple overlapping patents in MS, emphasizing the importance of non-infringing alternatives.
- Active in major jurisdictions, it influences competitive positioning until expiration (roughly 2032).
- Commercial strategies may extend into formulation patents and treatment protocols.
FAQs
1. Does this patent cover all combination therapies for MS?
No. It specifically claims combinations with interferon beta, fingolimod, or natalizumab, not other drugs.
2. Can other companies develop similar therapies without infringing?
Potentially. They would need to avoid the specific immunomodulators claimed and consider alternative dosing or agents.
3. When does the patent expire?
Expected expiration is around August 2031, considering patent term adjustments.
4. Are there challenges or litigations associated with this patent?
No publicly known litigations to date, but patent disputes in MS space are common.
5. How does this patent impact biosimilar development?
It creates a barrier for biosimilars that aim to combine glatiramer acetate with the protected immunomodulators until patent expiry.
References
- U.S. Patent and Trademark Office. "United States Patent No. 8,518,437." (2013).
- Teva Pharmaceuticals. "Patent family and legal status information." (USPTO records).
- European Patent Office. "Patent family documentation for EPXXXXXXX."
- U.S. Patent No. 7,585,781. "Glatiramer acetate compositions."
- U.S. Patent No. 8,225,753. "Combination therapies for MS."
More… ↓
⤷ Start Trial
|
